Valueworks LLC Has $5.74 Million Position in Eli Lilly and Company (LLY)
Valueworks LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% during the first quarter, Holdings Channel reports. The institutional investor owned 68,281 shares of the company’s stock after selling 2,055 shares during the period. Eli Lilly and makes up about 4.4% of Valueworks LLC’s holdings, making the stock its 7th largest position. Valueworks LLC’s holdings in Eli Lilly and were worth $5,743,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Joel Isaacson & Co. LLC raised its stake in shares of Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock worth $27,280,000 after buying an additional 9,680 shares in the last quarter. Washington Trust Bank raised its stake in shares of Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock worth $872,000 after buying an additional 4,990 shares in the last quarter. Bollard Group LLC raised its stake in shares of Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock worth $26,408,000 after buying an additional 8,153 shares in the last quarter. Finally, Sabal Trust CO raised its stake in shares of Eli Lilly and by 1.2% in the first quarter. Sabal Trust CO now owns 6,400 shares of the company’s stock worth $538,000 after buying an additional 75 shares in the last quarter. 75.59% of the stock is currently owned by institutional investors.
Shares of Eli Lilly and Company (LLY) traded up 0.32% on Monday, hitting $81.41. The company had a trading volume of 399,189 shares. The company has a 50-day moving average of $82.91 and a 200 day moving average of $81.72. The stock has a market cap of $85.89 billion, a PE ratio of 35.23 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.86 earnings per share. Analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.
LLY has been the topic of a number of analyst reports. BMO Capital Markets set a $71.00 price objective on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a report on Monday, July 17th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $87.00 price objective on shares of Eli Lilly and in a report on Wednesday, April 19th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $92.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a report on Saturday, April 29th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a report on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $88.27.
In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total value of $17,855,750.00. Following the completion of the sale, the insider now owns 124,475,804 shares in the company, valued at approximately $10,337,715,522.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock valued at $55,845,287 over the last 90 days. 0.20% of the stock is currently owned by insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.